FFA
MENS

Farther Finance Advisors’s Jyong Biotech MENS Stock Holding History

Farther Finance Advisors’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-204
Closed -$806 – 5952
2025
Q4 		$806 Buy
+204
New +$7.2K ﹤0.01% 4957

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Farther Finance Advisors's MENS Position: Q1 2026 in Review

Farther Finance Advisors sold out of Jyong Biotech (MENS) in Q1 2026, closing a stake of 204 shares — an estimated $806 sold.

Farther Finance Advisors first reported a position in MENS in Q4 2025 and held it in 1 quarter. The position peaked at $806 in Q4 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Farther Finance Advisors reported no remaining Jyong Biotech position as of Q1 2026 after selling out during the quarter.
  • Farther Finance Advisors sold 204 Jyong Biotech shares in Q1 2026, an estimated $806.
  • Farther Finance Advisors first reported a position in Jyong Biotech in Q4 2025 and held it in 1 quarter.
  • Farther Finance Advisors's Jyong Biotech position peaked at $806 in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.